Loading insider details...
Beta
Latest Form 4 (Jan 24, 2026): Grant/Award of 365,000 QNCX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 24, 2026 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 365,000 | n/a |
| Dec 8, 2025 | Quince Therapeutics, Inc. (QNCX) | Exercise/Conversion | 2,271 | $1.2K |
| Jun 23, 2025 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 37,736 | $45.3K |
| Feb 11, 2025 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 450,000 | n/a |
| Aug 21, 2024 | Quince Therapeutics, Inc. (QNCX) | Purchase | 2,155 | $1.2K |
| Jun 5, 2024 | Quince Therapeutics, Inc. (QNCX) | Exercise/Conversion | 56,061 | $30.8K |
| Feb 2, 2024 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 600,000 | n/a |
| Oct 26, 2023 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 75,000 | n/a |
| Aug 9, 2023 | Quince Therapeutics, Inc. (QNCX) | Purchase | 71,762 | $87.5K |
| Feb 2, 2023 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 225,000 | n/a |